Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

JNJ-87704916

Oncolytic virus · Kills target cells · developed by JOHNSON & JOHNSON

Phase 1 Most advanced trial
JNJ Developer
1 Registered trials

What is JNJ-87704916?

JNJ-87704916 is a recombinant oncolytic herpes simplex virus type 1 that is given by intratumoral injection. It preferentially infects and replicates in tumor cells, causing their lysis, and the released tumor antigens are reported to induce a tumor-specific cytotoxic T-lymphocyte response against nearby tumor cells. It is studied in neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oncolytic virus
Mechanism
Kills target cells
Pathways
tumor cell lysis, anti-tumor immune response
Therapy area
Oncology
Developer
JOHNSON & JOHNSON (JNJ)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06311578 Phase 1 Neoplasms Recruiting JNJ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Neoplasms

More from JOHNSON & JOHNSON

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the JNJ page.

Follow JNJ, the company behind JNJ-87704916

See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JNJ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.